| | |
 | | | Saving Lives and Taking Gains: Why I'm Invested in Biotech | | Marc Lichtenfeld | Chief Income Strategist | The Oxford Club | | | | | Editor's Note: Here at Profit Trends, our experts are passionate about tracking the latest trends.
That's why we're so excited about the upcoming 2019 American Health & Wealth Summit featuring biotech investing expert Marc Lichtenfeld and former Speaker of the House Newt Gingrich.
Marc, who spearheads our sister e-letter Wealthy Retirement, has partnered with Gingrich to reveal the most innovative and profitable opportunities in the healthcare sector.
Don't miss their one-of-a-kind event on Thursday, July 18, at 1 p.m. ET. It's entirely free to attend. Click here to reserve your seat!
To gear up for the event, today's article comes from Marc. In it, he outlines why biotech is one of your best bets for big returns this year.
Read on...
- Rebecca Barshop, Managing Editor | | | | | Investing is serious work.
If you're like most people, your retirement won't be - or wasn't - secured by your job. Even if you're fortunate enough to have a pension, that income alone probably won't take care of all your expenses in retirement. That's why it's critical to invest for the future and to start early.
Once you have your long-term plan in place and some extra funds left over, it's fun to speculate in the market. When it's successful, you can make big money... just from a small investment. And usually the companies that you speculate on are exciting and innovative.
It's one of the reasons I love the biotech sector.
Some of these companies make your average speculative stock look like the ultra-conservative Coca-Cola (NYSE: KO). In other words, many biotechs fly all over the place.
When stocks are down and the biotech sector is getting hit, some small cap names can fall 5% or more in a day.
But when things go right, boy do they ever. A small biotech company with positive clinical trial data on one of its drugs can surge 50%, 75%, even 100% in one trading session. | | | And for the companies that become successful, the amount of money that can be made is mind-boggling.
For example, Celgene Corp. (Nasdaq: CELG) went public in 1990. If you had waited five years after its initial public offering (IPO) to buy the stock (I usually don't like to buy biotech IPOs right away - I prefer to give the company a little bit of time to prove itself), you would have bought the stock at $5.31.
Today, Celgene is at $101.44. A 2,000-share investment of $10,620 would now be worth $202,880.
That's a 1,810% return in 21 years.
There are many other examples.
Biotech has another unique feature. Not only are the potential gains better than those in any other sector of the market, but people actually enjoy following the progress of the stocks.
An investor can own a stock like Target (NYSE: TGT) and make some money. But do they really get excited when the same-store sales report comes out every month?
On the other hand, imagine owning a stock like Kite Pharma (formerly traded on the Nasdaq), which develops cutting-edge cancer immunotherapy products.
Its patented KTE-C19 therapy for lymphoma has been shown to be effective in two-thirds of clinical trial subjects (lymphoma patients who haven't responded to other treatments). More than 40% of subjects show complete remission.
These successes in treating seemingly terminal forms of cancer led Gilead Sciences (Nasdaq: GILD) to acquire Kite for $11.9 billion. Kite shareholders earned triple-digit returns from the deal.
That's incredibly exciting. And biotech investors are often as jazzed about the medical advances that these companies make as they are about the stock price advances.
I don't ever recommend you let your emotions be a factor in your investing, but it's hard not to be happy when you know that the company you invested in will drastically improve or even save the lives of sick patients.
In the Thick of It
On Thursday, July 18, at 1 p.m. ET, I'll be hosting The 2019 American Health & Wealth Summit alongside former Speaker of the House Newt Gingrich. Anyone who's anyone in healthcare and healthcare investing will be tuning in.
During the event, Newt and I will discuss the medical breakthrough that will solve America's broken healthcare system and will make smart investors a lot richer. In fact, I'll outline five companies that are poised to profit from this new biotech trend.
To attend the free 2019 American Health & Wealth Summit, simply click here to register. You won't want to miss it.
If you have a little extra play money, this is the easiest way to get familiar with the sector. You can score some huge profits and may learn something that could help someone suffering from a particular condition or disease.
See you on the 18th.
Good investing,
Marc | | | | |  | | | | | |  |  | | | | David Fessler | July 3, 2019 Here are two battery storage stocks that can expose you to the fastest-growing area of the energy sector. Read More | | | | |  | | | | Matthew Carr | July 2, 2019 Who are the biggest winners and losers in the cannabis space? Find out here. Read More | | | | |  | | | | Anthony Summers | July 1, 2019 Healthcare has become one of the most politicized sectors of the market. But that may be a blessing in disguise for those seeking a bargain buy. Read More | | | | | | | | | | |
|
The Oxford Club is a financial publisher that does not offer any personal financial advice or advocate the purchase or sale of any security or investment for any specific individual. Members should be aware that although our track record is highly rated by an independent analysis and has been legally reviewed, investment markets have inherent risks and there can be no guarantee of future profits. The stated returns may also include option trades. 
No comments:
Post a Comment